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Abstract
Pulmonary arterial hypertension (PH) is associated with high mortality due to right ventricular failure and hypoxia, therefore
to understand the mechanism by which pulmonary vascular remodeling initiates these processes is very important. We used
a well-characterized monocrotaline (MCT)-induced rat PH model, and analyzed lung morphology, expression of cytokines,
mitogen-activated protein kinase (MAPK) phosphorylation, and phosphatidylinositol 3-kinase-Akt (PI-3k-Akt) pathway and
nuclear factor (NF)-kB activation in order to elucidate the mechanisms by which sildenafil’s protective effect in PH is exerted.
Besides its protective effect on lung morphology, sildenafil suppressed multiple cytokines involved in neutrophil and
mononuclear cells recruitment including cytokine-induced neutrophil chemoattractant (CINC)-1, CINC-2a/b, tissue inhibitor
of metalloproteinase (TIMP)-1, interleukin (IL)-1a, lipopolysaccharide induced CXC chemokine (LIX), monokine induced by
gamma interferon (MIG), macrophage inflammatory protein (MIP)-1a, and MIP-3a. NF-kB activation and phosphorylation
were also attenuated by sildenafil. Furthermore, sildenafil reduced extracellular signal-regulated kinase (ERK)1/2 and p38
MAPK activation while enhanced activation of the cytoprotective Akt pathway in PH. These data suggest a beneficial effect
of sildenafil on inflammatory and kinase signaling mechanisms that substantially contribute to its protective effects, and
may have potential implications in designing future therapeutic strategies in the treatment of pulmonary hypertension.
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Introduction
Pulmonary arterial hypertension (PH) is a progressive and
incurable disease that progresses to severe right heart failure. The
disease is characterized by increase of the pulmonary vascular
resistance due to obstructive proliferative changes in the lung
microcirculation [1]. Our knowledge regarding the multiple
pathological processes leading to the evolution of microvascular
injury is still limited. Multiple lines of evidence support that
vasoconstriction as well as inflammatory processes precede the
remodeling of the pulmonary arterioles [2]. Endothelial dysfunc-
tion interferes at various levels with the microvascular injury
characterized by medial hypertrophy, intimal proliferative chang-
es, adventitial thickening with perivascular inflammatory infil-
trates. These alterations as well as increased level of reactive
oxygen species account for decreased apoptosis and increased
proliferative vascular remodeling has significant role in the
pathogenesis and progression of PH [3].
Our current therapeutic approach is based on application of
vasodilator drugs despite that inflammation seems to be an
important factor in the pathogenesis of PH [4].
Data from human studies as well as from monocrotaline (MCT)
induced experimental rat PH model support that alveolar
macrophages are the main source of cytokines and chemokines.
The MCT treatment jeopardize pulmonary endothelial cells [5,6]
causing pulmonary artery smooth muscle (SM) hypertrophy with
persistent pulmonary hypertension [7]. MCT not only injures the
pulmonary arteries but also induces alveolar edema, alveolar
septal cell hyperplasia, and occlusion of pulmonary veins [8,9].
However, the pulmonary epithelium also produces these proin-
flammatory mediators, and lymphocytes and macrophages infil-
trates as well as increased local expression of chemokines were
found in the plexiform lesions of PH [10,11].
Sildenafil, an inhibitor of phosphodiesterase type 5 (PDE-5) is
widely used in the treatment of PH, and was demonstrated to
improve exercise capacity, symptoms, and haemodynamics
[12,13]. However, the precise molecular mechanism of the
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protective effect of this drug is not completely understood. PDE-5
degrades the second messenger cGMP to GMP. Sildenafil by
inhibiting PDE-5 increases intracellular cGMP level leading to
smooth muscle cell (SMC) relaxation and produces beneficial
effect on vascular remodeling and vasodilation through several
pathways.
In a simple and widely accepted animal PH model, following
two weeks of a single subcutaneous injection of MCT, rapid
induction of severe pulmonary vascular disease consisting of
pulmonary vascular remodeling and elevated pulmonary pressure
can be observed with morphology similar to that observed in the
human disease [14,15].
In the present work using MCT induced rat PH, we investigated
the protective role of sildenafil in the lung, and the mechanisms by
which it contributed to attenuating the MCT induced inflamma-
tory processes. We aimed to characterize changes in the cytokine
network using a comprehensive array of 29 cytokines. Further-
more, we explored nuclear factor (NF)-kB activation, mitogen-
activated protein kinases (MAPK) and the phosphatidylinositol 3-
kinase-Akt (PI-3K)-Akt pathway.
Materials and Methods
Materials
Protease inhibitor cocktail, phosphatase inhibitor cocktail and
MCT were purchased from Sigma Aldrich Co. (Budapest,
Hungary). All reagents were of the highest purity commercially
available.
Solution protocols
MCT was dissolved in 0.5N HCl and the pH was adjusted to
7.4 using 0.5N NaOH.
The sildenafil solution was obtained by pulverizing 100 mg
sildenafil tablets (Pfizer) dissolved to 0.2 mg/ml in drinking water.
Animals were treated with freshly made solutions.
Experimental protocol
The investigation conformed to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health, and was approved by the Animal Research Review
Committee of the University of Pe´cs, Hungary. All animals were
housed one or two per cage, under optimal laboratory conditions
(controlled temperature, humidity and 12:12 h- light-dark cycles)
with free access to water and standard rodent chow. The animals
were randomly assigned into four groups (i) Six animals were
allocated to Sham group (n= 6) receiving subcutaneous injection
of isotonic saline (0.1 ml/kg) on day 0. (ii) Eight animals were
allocated to Sham+SLD group (n= 8) receiving subcutaneous
injection of isotonic saline (0.1 ml/kg) on day 0 and sildenafil
(2 mg/kg per day, per os, in the drinking water) from day 0 to day
28. (iii) Eight animals were allocated to PH group (n= 8) receiving
60 mg/kg subcutaneous injection of MCT on day 0. (iv) Eight
animals were allocated to PH+SLD group (n= 8) receiving
60 mg/kg subcutaneous injection of MCT on day 0 and sildenafil
(2 mg/kg per day, per os, in the drinking water) from day 0 to day
28.
Lung histology
Lungs were removed on day 28 under deep anesthesia, quickly
blotted free of blood, weighed, and processed as required for
histology and immunohistology. Lungs from 3 and 4 rats of control
(Sham) and each of the other groups, respectively, were fixed in
6% formalin, embedded into paraffin and 5 mm thin sections were
cut with a microtome. Sections were stained with haematoxylin–
eosin and digital photos were taken. Average wall thickness of
alveolar sac was determined at randomly chosen 25 different sites
in each section by an expert who was blind to the experiment.
Macrophages were counted in 5 non-overlapping high power
fields (2006) in each sections by an expert who was blind to the
experiment.
Immunohistochemical staining
Slides were deparaffinized in xilene, rehydrated in graded
ethanol series, and washed in distilled water. Heat induced epitope
retrieval was performed by boiling the tissue sections in citrate
buffer (HISTOLS Citrate Buffer, cat# 30010; Histopathology
Ltd.) in a microwave oven at 750 W followed by cooling at room
temperature for 20 minutes. Slides were washed in tris buffered
saline (TBS) solution (pH=7,6) followed by blocking of endoge-
nous peroxidase (Peroxidase blocking, cat#30012, Histopathology
Ltd.) for 10 minutes at room temperature. Slides were washed in
TBS. Nonspecific sites were blocked (Background Blocking Protein
Solution, cat#30013, Histopathology Ltd.) for 10 minutes at room
temperature. Without washing, the following primary antibodies
were applied: CD34: cat# 10097.10, clone: Q19-E, rabbit clonal
antibody 1:200 dilution, Anti-NF-kB p65 (phospho S536) antibody
(Abcam, cat#ab86299 in 1:20 dilution). Incubation with the
primary antibodies was performed for 1 hour at room temperature
followed by washing in TBS. Secondary antibody (HISTOLS -R
Detection System, anti-rabbit, Histopathology Ltd.) was applied
for 30 minutes at room temperature followed by repeated washing
in TBS. Sections were incubated with 3-amino-9-ethylcarbazol
(HISTOLS -Resistant AEC Chromogen/Subsrtate System, cat#
30015.K, Histopathology Ltd.) or 3,39-Diaminobenzidine (HIS-
TOLS DAB Chromogen/Subsrtate System, cat#30014.K, His-
topathology Ltd.), washed in distilled water, counterstained with
haematoxylin followed by incubation in tap water. Negative
control was incubated with antibody diluent instead of the primary
antibody and applying anti-rabbit secondary antibody. Sections
were then dehydrated, cleared in xilene and mounted with
permanent mounting medium.
Cytokine measurements
The cytokine array assay was performed on lung homogenates
from 3 and 4 rats of control (Sham) and each of the other groups,
respectively, using Rat Cytokine Array kit (R&D Systems;
Biomedica Hungaria, Hungary). These arrays are based on
binding between sample proteins and carefully selected capture
antibodies spotted on nitrocellulose membranes. We examined
tissue samples from all the 4 groups: Sham, Sham+ SLD, PH and
PH+SLD groups. The array was performed as described by the
manufacturer, similarly to our previous study [16]. Briefly, lung
samples were homogenized in PBS with protease inhibitor. Triton
Figure 1. Effects of sildenafil treatment on histological changes of the lung. Formalin fixed lungs of untreated (Sham), sildenagfil (Sham+
SLD), MCT (PH) and MCT plus sildenafil treated (PH+SLD) rats (n = 3–4) were subjected to histopathological analysis. Representative HE stained
sections (A), macrophage infiltration (B), the mean wall thickness of alveolar sac (C), representative high power HE images of a blood vessel (D) and
representative CD-34 immunohistochemistry images (E) indicating vascularization and vascular remodeling are presented. Macrophages and blood
vessels are indicated by filled and empty arrows, respectively. Bar values are mean6S.E.M. *** significantly different from Sham group (p#0.05),
+++ significantly different from PH group (p#0.05) by ANOVA, post hoc Bonferroni test.
doi:10.1371/journal.pone.0104890.g001
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X-100 was added to the final concentrations of 1%. After blocking
the array membranes for 1 hour and adding the reconstituted
detection antibody cocktail for another 1 hour at room temper-
ature, the membranes were incubated with 1 ml of tissue
homogenates containing 300 mg proteins at 2–8uC overnight on
a rocking platform. After washing with buffer three times and
addition of horseradish peroxidase-conjugated streptavidin to each
membrane, the plates were exposed to a chemiluminescent
detection reagent (Amersham Biosciences, Hungary), then were
placed facing up to an X-ray film cassette. The array was run in
duplicate sets. Developed films were scanned and analysed by
densitometry. The pixel volumes of the bands were determined
using the NIH ImageJ software, with the values in ratios of
intensity.
Immunoblotting
Lung tissue samples from 3 and 4 rats of control and each of the
other groups, respectively, were homogenized in ice-cold isotonic
Tris buffer (50 mM, pH 8.0) containing phosphatase and protease
inhibitor cocktail (each 1:1000; Sigma–Aldrich). After sonication,
proteins were precipitated by trichloroacetate, washed three times
with 220uC acetone, dissolved in Laemmli sample buffer,
separated on 10% sodium-dodecil-sulfate (SDS)–polyacrylamide
gels, and transferred to nitrocellulose membranes. After blocking
for 2 hours with 3% nonfat milk in Tris-buffered saline, the
membranes were probed overnight at 4uC with antibodies
recognizing the following antigens: total-p38MAPK, phospho-
p38 MAPK (Thr180/Tyr182), phospho-extracellular signal-regu-
lated kinase (ERK)1/2 (Thr202/Tyr204), total ERK1/2, total
GSK-3b, phospho-GSK-3b (Ser9), phospho-Akt (S473), total Akt,
total-NF-kB, phospho-NF-kB (Ser536) (each 1:500 dilution, Cell
Signaling Technology). The membranes were washed six times for
5 minutes in Tris-buffered saline (pH 7.5) containing 0.2% Tween
before addition of goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody (1:3000 dilution; Bio-Rad). The
protein bands were visualized with enhanced chemiluminescence
(ECL) labeling using an ECL immunoblotting detection system
(Amersham Biosciences). Developed films were scanned and the
pixel volumes of the bands were determined using the NIH ImageJ
software, with the values in ratios of intensity. Each experiment
was repeated at least four times.
Data analysis
The data are expressed as mean 6 standard deviation. Data of
alveolar sac thickness and densitometry were analyzed using the
Kolmogorov-Smirnov normality test followed by the one-way
Anova test and Bonferroni post hoc multiple comparison test.
Differences were considered significant at p,0.05. Analyses were
performed using IBM SPSS Statistics 20.
Results
Effects of sildenafil treatment on histological changes of
the lung
Lung tissue of half of the animals in each group was subjected to
histopathological study. Figure 1A demonstrates haematoxylin–
eosin stained section of a Sham group rat; its alveolar sac and
bronchioles with normal epithelium. There was a baseline level of
macrophage infiltration (Figure 1B), the mean wall thickness of
alveolar sac was 3.3160.88 mm (Figure 1C), and vascular
histology showed normal morphology (Figure 1D). CD-34 immu-
nohistochemistry that indicates vascularization and vascular
remodeling [17] showed sporadic weak positivity (Figure 1E).
Sildenafil treatment alone did not cause any change in the
aforementioned parameters (Figure 1). In MCT treated animals,
the mean wall thickness of alveolar sac increased to 9.7762.63 mm
(p#0.05) (Figure 1C) that was accompanied by a markedly
increased macrophage infiltration (Figure 1A, B). We could also
detect extensive vascular remodeling in the small pulmonary
vessels- with intimal and medial hypertrophy of the muscular
arteries and arterioles (Figure 1D,E). Sildenafil improved histo-
logical appearance of both the lung tissue (Figure 1A) and the
blood vessels (Figure 1D,E), decreased macrophage infiltration
(Figure 1B) as well as the alveolar sac wall thickness to
8.161.47 mm (p#0.05) (Figure 1C).
Effects of sildenafil treatment on cytokine expressions
Since the histopathological study indicated inflammatory pro-
cesses upon MCT treatment, we investigated the expression of 29
cytokines in our model. MCT significantly increased the expression
of several cytokines (Figure 2) including the chemokines of the CXC
group such as cytokine-induced neutrophil chemoattractant
(CINC)-1, CINC-2a/b, lipopolysaccharide induced CXC chemo-
kine (LIX) and monokine induced by gamma interferon (MIG).
Expression of other chemoattractant proteins like macrophage
inflammatory protein (MIP)-1a and MIP-3a was also increased.
Levels of interleukin (IL)-1a, tissue inhibitor of metalloproteinase
(TIMP)-1 were also elevated in MCT treated lungs. Sildenafil
treatment attenuated the activation of these cytokines, as measured
by a cytokine array system (Figure 2B–I). Sildenafil treatment alone
did not affect cytokine expression significantly (Figure 2A).
Effects of sildenafil treatment on NF-kB activation
Expression of most the aforementioned cytokines that were
significantly induced by MCT treatment are regulated by NF-kB
transcription factor. Therefore, we determined NF-kB activation
by immunoblotting and immunohistochemistry utilizing phospho-
NF-kB p65 specific primary antibody among the various groups.
Under our experimental conditions, none of the treatments
affected expression level of NF-kB. On the other hand, we
observed increased phosporylation thereby activation of NF-kB
[18] in MCT treated lung tissues, which was diminished in
sildenafil treated animal lungs (Figure 3A). Phospho-NF-kB p65
immunohistochemistry showed sporadic patchy weak background
positivity in the Sham group. A very few of the nuclei
demonstrated strong positive staining indicating nuclear translo-
cation of NF-kB. NF-kB activation and nuclear translocation was
basically identical to control among the sildenafil treated animals.
MCT treatment caused a massive activation and nuclear
translocation of NF-kB that was significantly diminished by
sildenafil treatment (Figure 3B).
Effect of sildenafil on PI-3K-Akt and MAPK signaling
pathway
NF-kB activation is regulated by various kinase signaling
pathways including PI-3K-Akt and MAPK pathways [19].
Figure 2. Effects of sildenafil treatment on cytokine expressions. Nitrocellulose based rat cytokine array assay was performed on lung
homogenates of untreated (Sham), sildenagfil (Sham+SLD), MCT (PH) and MCT plus sildenafil treated (PH+SLD) rats (n = 3–4). Bar diagrams represent
mean6S.E.M. pixel densities of the immunoblots. *** significantly different from Sham group (p#0.05), +++ significantly different from PH group (p#
0.05) by ANOVA, post hoc Bonferroni test.
doi:10.1371/journal.pone.0104890.g002
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Figure 3. Effects of sildenafil treatment on NFkB activation and nuclear translocation. NFkB activation and nuclear translocation was
assessed by immunoblotting (A) and immunohistochemistry (B) utilizing phospho-NF-kB p65 (A,B) and NF-kB (A) specific primary antibodies. Bar
diagrams (A) of the mean pixel densities6S.E.M. and representative immunohistochemistry images (B) of 3 to 4 animals are presented. The phospho-
NFkB p65 bands were normalized to the NFkB band. *** significantly different from Sham group (p#0.05), +++ significantly different from PH group
(p#0.05) by ANOVA, post hoc Bonferroni test.
doi:10.1371/journal.pone.0104890.g003
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Therefore, we assessed the activation of these pathways by
immunoblotting utilizing phosphorylation-specific primary anti-
bodies.
Expression of Akt or its downstream target, glycogen synthase
kinase (GSK)-3b was not affected by any of the treatment. The
phosphorylation thereby activation of Akt was not detectable in
control lung tissues (Figure 4). Sildenafil alone slightly increased
Akt activation, although, it did not reach the level of statistical
significance. MCT treatment significantly increased Akt phos-
phorylation that was further enhanced by sildenafil administration
tissues (Figure 4). The phosphorylation of Akt’s downstream target
GSK-3b showed similar patter among the different groups as that
of Akt verifying Akt activation (Figure 4).
Since cGMP was reported to regulate ERK1/2 and p38 among
the MAPKs [20], we studied the effect of MCT and sildenafil on
them. Expression of ERK1, 2 and p38 was not affected
significantly by any of the treatment. In the control lungs with
or without sildenafil treatment, a slight phosphorylation of ERK1/
2 was observed (Figure 5). In MCT treated lungs a moderate
activation of ERK1/2 occurred that was slightly decreased by
sildenafil treatment, however, none of these changes reached the
level of statistical significance (Figure 5). The p38 MAPK
activation/phosphorylation in control lungs was undetectable that
was slightly elevated by sildenafil treatment. A robust activation of
p38 MAPK was observed when MCT induced PH occurred that
was significantly diminished by sildenafil (Figure 5).
Discussion
Vasodilators - including sildenafil, a PDE-5 inhibitor - are
widely used to treat pulmonary arterial hypertension. Clinical data
are supporting the benefits of this treatment in terms of
improvement of symptoms, exercise capacity, haemodynamics,
and possible outcome [21]. However, it is still unclear whether
sildenafil affects microvascular injury via mechanisms that are
independent from or additional to vasodilation. Increased
pulmonary arterial pressure in PH results from a combination of
pulmonary vasoconstriction, vascular remodelling, inflammation
and, in some cases, in situ thrombosis. Elevated circulating levels
of the proinflammatory cytokines IL-1b, IL-6, macrophage
inflammatory protein-1a, and P-selectin have been observed in
patients [22,23]. A role for inflammation in the development of
IPAH is supported by enhanced pulmonary expression of various
cytokines and chemokines, such as fractalkine and their association
with inflammatory cell infiltrates in severe PAH [24,25]. In the
MCT model, besides thickened, obstructed blood vessels and
increased CD-34 immunoreactivity, we observed increased
macrophage infiltration and increased wall thickness of aleolar
sacs. Former findings reflect to vascular remodeling and vascular-
ization, while the latter ones are due to inflammatory processes.
These findings are in line with alterations described in earlier
studies [26,27]. Sildenafil’s ability to ameliorate all the aforemen-
tioned pathological changes, suggested that it possesses
anti-inflammatory characteristics. Anti-inflammatory effects of
sildenafil were controversial in the earlier studies [28,29] however
Figure 4. Effect of sildenafil on Akt activation. Effect of Sildenafil and MCT treatment on Akt expression (A) and activation (B) as well as on GSK-
3b expression (C) and phosphorylation (D) was determined by immunoblotting utilizing protein- and phosphorylation specific primary antibodies.
The bar diagrams represent pixel volumes6S.E.M. of pAkt and pGSK-3b bands. The bands were normalized to the appropriate Akt and GSK-3b bands.
*** significantly different from Sham group (p#0.05), +++ significantly different from PH group (p#0.05) by ANOVA, post hoc Bonferroni test.
Phospho-Akt and GSK-3b are denoted as pAkt and pGSK-3b.
doi:10.1371/journal.pone.0104890.g004
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recent studies in different models [30,31] showed findings, which
are in line with our results.
We found that sildenafil treatment significantly reduced the
MCT induced expression of a number of cytokines and
chemokines in lung homogenates by using a rat cytokine array.
Among them, CINC-1 and CINC-2a/b have neutrophil chemo-
tactic activity and promote neutrophil-facilitated cell damage in
the lungs [32,33]. In previous studies using an acute lung injury
model, serum CINC-1 levels correlated with the elevated lung
CINC-1 levels suggesting that circulating CINC-1 levels could be
used as an early marker for the subsequent development of organ
inflammation and injury [34]. LIX is a chemokine belonging to
the CXC chemokine group, produced by type-II alveolar
epithelial cells and NF-kB regulates its expression [35]. LIX
facilitates neutrophil recruitment which can promote oxidative
stress induced damages [36]. Similarly, MIG is another overex-
pressed, effective chemo-attractant for mononuclear cells from the
CXC chemokine group which can also contribute to cell death
[37]. MIP chemokines released from macrophages activate
granulocytes and lymphocytes and enhance the synthesis of
proinflammatory cytokines such as IL-1, IL-6 and tumor necrosis
factor (TNF)-a, which play a crucial role in the pathomechanism
of PH. Fartoukh et al. demonstrated increased MIP-1a mRNA
expression in human lung biopsy specimens of PH patients [22].
Humbert et al showed slight increases in both IL-1 and IL-6 serum
concentrations in severe PH patients [23]. These cytokines
produced mainly by activated macrophages, neutrophils, epithelial
and endothelial cells initiate inflammatory responses and oxidative
stress [38,39].
Most of the aforementioned cytokines’ and chemokines’
expression is regulated by NF-kB, which was reported to activate
a number of cytokine and growth factor genes associated with PH
[40,41]. NF-kB is retained in the cytoplasm in its inactive form by
its inhibitor, I-kB, which is subject to phosphorylation mediated
degradation. A number of signaling kinases including MAPKs
phosphorylate thereby activate I-kB kinase. After removal of I-kB,
nuclear localization signal of NF-kB becomes unmasked, it
translocates to the nucleus where it is activated by phosphorylation
and acetylation to stimulate NF-kB dependent gene expression
[42]. Accordingly, we confirmed our cytokine array findings by
demonstrating that sildenafil attenuated MCT induced NF-kB
activation. We performed NF-kB immunohistochemistry to
identify the cells responsible for the cytokine and chemokine
production, and in accord with previous reports by others [38,39]
we found that endothelial and epithelial cells as well as the
infiltrating inflammatory cells all contributed to this process. A
previous report [43] highlighted the relevance NF-kB activation in
PH patients, while NF-kB’s direct inhibition protected against the
development of MCT induced PH [44]. Besides the aforemen-
tioned cytokines and chemokines, NF-kB regulates matrix
metalloproteinase (MMP) expression too. Most probably, the
increased TIMP-1 expression we observed developed as a
compensatory mechanism [45] for the MCT induced MMP
expression.
PI-3K–Akt signaling plays an essential role in regulating a
number of cellular processes, including cellular growth and
proliferation, migration and cell survival. PI-3K and Akt proteins
are expressed constitutively in cultured vascular smooth muscle
cells (VSMCs). Activated Akt has been found in vascular
remodeling after vascular injury accompanied by VSMC prolif-
eration [46]. Activation of Akt is tightly coupled to proliferation of
VSMCs involved in vascular remodeling [47]. Pulmonary arterial
Figure 5. Effect of sildenafil on ERK1/2 and p38 MAPK activation. Effect of Sildenafil and MCT treatment on ERK 1 and 2 expression (A) and
activation (B) as well as on p38 MAPK expression (C) and phosphorylation (D) was determined by immunoblotting utilizing protein- and
phosphorylation specific primary antibodies. The bar diagrams represent pixel volumes6S.E.M. of pERK1/2 and pp38 MAPK bands. The bands were
normalized to the appropriate ERK1/2 and p38 MAPK bands. *** significantly different from Sham group (p#0.05), +++ significantly different from PH
group (p#0.05) by ANOVA, post hoc Bonferroni test. Phospho-ERK1/2 and p38 MAPK are denoted as pERK1/2 and pp38 MAPK.
doi:10.1371/journal.pone.0104890.g005
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smooth muscle cell (PASMC) phenotype switching, which is
characterized by changes in smooth muscle (SM)-specific gene
expression, contributes to vascular remodeling in PH. In addition,
it has been shown that the transcription of SM-specific genes is
modulated by cytoskeleton rearrangement. PI-3K-Akt pathway
plays an important role in the modulation of PASMCs cytoskel-
eton rearrangement and phenotype switching [48]. The PI-3k-Akt
pathway activates endothelial nitric oxide synthase (eNOS), and
inactivates GSK-3b. eNOS activation can promote the vascular
smooth muscle cell relaxation, and the inhibition of GSK-3b can
prevent mitochondrial permeability transition which would lead to
necrotic cell death [49]. In our PH model, Akt activation and
GSK-3b inactivation may be interpreted as an unsuccessful
compensatory mechanism against the oxidative and inflammatory
damage induced by the MCT treatment. When augmented by
sildenafil it could contribute to overcome the harmful conse-
quences of the MCT treatment.
The MAPKs are a family of central signaling molecules that
respond to numerous stimuli by phosphorylating a variety of
substrates including transcription factors, enzymes, and other
kinases, thereby orchestrating cellular proliferation, differentiation,
survival, apoptosis and inlammatory processes. Also, the remod-
eling of vasculature had been related to MAPKs [50–52].
Inhibition of the downstream ERK1/2 signaling pathway
activation prevents pulmonary vascular remodeling, elevated right
ventricular pressure and improves right ventricular hypertrophy in
MCT- and chronic hypoxia-induced PH model [53,54]. Zeng et al
showed that the phosphorylation levels of ERK1/2 are signifi-
cantly increased in MCT induced PH rat model and sildenafil
treatment can inhibit the increased expression of ERK phosphor-
ylation in this model [50]. Fibroblasts in pulmonary arteries
express all four isoforms of p38 MAPK [55]. Using the p38
MAPK inhibitor in the chronic hypoxic and MCT model resulted
in lower right ventricular systolic pressure and right ventricular
hypertrophy in the drug treated animals. Lu et al found an
increase in p38 MAPK activity in MCT-treated rat lungs, and
demonstrated that the production and effect of many of the
potential inflammatory mediators in PH were associated with
activation of the p38 MAPK signaling pathway. A selective p38
MAPK inhibitor significantly attenuated the expression of
inflammatory cytokines in this study [49]. In our experimental
model, pulmonary hypertension activates ERK1/2 and p38
MAPK, but sildenafil partially suppresses their activation ulti-
mately preventing the progression of vascular remodeling and
inflammation in PH that is completely in line with the
aforementioned findings.
In conclusion, in our experimental model, elevated cGMP level
by sildenafil most probably via activating a protein kinase G
induced a crosstalk between kinase signaling systems [20]. It results
in sufficient enhancement of Akt activation to overcome the
pathologic remodeling processes induced by the MCT treatment,
decrease of MAPK activation and NF-kB nuclear translocation.
Latter, in turn, causes decreased cytokine and chemokine
production reducing inflammatory cell infiltration and edema
formation. All these data suggest a novel mechanism for the
beneficial effects of sildenafil in PH that is independent and
additional to its main vasodilatory effect.
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